dc.contributor
[Mas Marin J, Molina- Olano M] Unitat de Farmàcia Clínica i Atenció Farmacèutica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Universitat de Barcelona (UB), Barcelona, Spain. [Rudi Sola] Unitat de Farmàcia Clínica i Atenció Farmacèutica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Universitat de Barcelona (UB), Barcelona, Spain. Servei de Farmàcia, Hospital General de Granollers (HGG), Granollers, Spain. [Miserachs-Aranda N] Unitat de Farmàcia Clínica i Atenció Farmacèutica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Universitat de Barcelona (UB), Barcelona, Spain. Servei de Farmàcia, Fundació Hospital de l’Esperit Sant, Santa Coloma de Gramenet, Spain. [Montoliu Alcón P] Unitat de Farmàcia Clínica i Atenció Farmacèutica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Universitat de Barcelona (UB), Barcelona, Spain. Servei de Farmàcia, Hospital Universitari Sagrat Cor, Barcelona, Spain. [De Pourcq JT] Unitat de Farmàcia Clínica i Atenció Farmacèutica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Universitat de Barcelona (UB), Barcelona, Spain. Servei de Farmàcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
dc.contributor
Hospital General de Granollers
dc.contributor.author
Mas Marin, Joan
dc.contributor.author
Molina Olano, Marina
dc.contributor.author
Rudi Sola, Nuria
dc.contributor.author
Miserachs-Aranda, Núria
dc.contributor.author
Montoliu-Alcón, Paula
dc.contributor.author
De Pourcq, Jan Thomas
dc.date.accessioned
2025-11-13T20:42:24Z
dc.date.available
2025-11-13T20:42:24Z
dc.date.issued
2025-11-12T09:06:20Z
dc.date.issued
2025-11-12T09:06:20Z
dc.identifier
Mas Marin J, Molina-Olano M, Sola NR, Miserachs-Aranda N, Montoliu Alcón P, De Pourcq JT, et al. Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain. Clin Rheumatol. 2025 Sep;44(9):3445-3458.
dc.identifier
http://hdl.handle.net/11351/14061
dc.identifier
10.1007/s10067-025-07568-9
dc.identifier.uri
http://hdl.handle.net/11351/14061
dc.description.abstract
Biosimilars; Rheumatoid arthritis; Treatment patterns
dc.description.abstract
Biosimilars; Artritis reumatoide; Patrons de tractament
dc.description.abstract
Biosimilares; Artritis reumatoide; Patrones de tratamiento
dc.description.abstract
The objective of this study is to compare the effectiveness of reference biologic medicines used in the treatment of rheumatoid arthritis (RA) specifically adalimumab, etanercept, and infliximab, with corresponding biosimilar medicines, based on an exploratory analysis of clinical data obtained in patients treated with these medicines in five hospitals in the region of Catalonia, Spain.
There is a consultation of the database of the Registry of Patients and Treatments of the Catalan Health Service: extraction of data from adult patients diagnosed with moderate and severe active RA and with active prescription of at least one biological drug (reference or biosimilar) or JAK inhibitor. To compare the effectiveness of each reference biologic with its biosimilar, differences in mean DAS28-ESR values before and after treatment were assessed for adalimumab and its biosimilar, etanercept and its biosimilar, and infliximab and its biosimilar.
The study consisted of 643 patients. The most dispensed medicines were anti-TNFs, with 303 patients on treatment. Thirty-six percent of all patients were using biosimilars. No statistically significant differences were observed in any of the three comparisons between the reference biologic medicine and its biosimilar. These findings suggest that biosimilars have comparable effectiveness to reference biologics in reducing DAS28-ESR; in addition, they can provide substantial savings to public health systems.
A significant number of patients diagnosed with moderate to severe active RA were treated with biological medicines and receiving the available biosimilar treatments. Future research should be conducted to confirm comparable effectiveness found to their reference biologic medicines in this exploratory analysis. Key Points • Biosimilar use: 36% of rheumatoid arthritis (RA) patients in Catalonia are treated with biosimilars, exceeding the 12% recommendation. This reflects growing acceptance of these alternatives. • Comparative effectiveness: Biosimilars of adalimumab, etanercept, and infliximab showed comparable therapeutic benefit to their reference biologics in reducing disease activity in active rheumatoid arthritis. • Real-world data: The study provides real-world data from five hospitals, making biosimilar medicines a viable choice for rheumatologists in routine rheumatoid arthritis management.
dc.description.abstract
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
Clinical Rheumatology;44(9)
dc.relation
https://www.doi.org/10.1007/s10067-025-07568-9
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anticossos monoclonals
dc.subject
Productes biològics
dc.subject
Artritis reumatoide
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
dc.subject
CHEMICALS AND DRUGS::Complex Mixtures::Biological Products
dc.subject
DISEASES::Musculoskeletal Diseases::Joint Diseases::Arthritis::Arthritis, Rheumatoid
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos
dc.subject
ENFERMEDADES::enfermedades musculoesqueléticas::artropatías::artritis::artritis reumatoide
dc.title
Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
